Table 4.

Treatment-emergent adverse events (all grades) occurring in ≥10% of subjects excluding injection-related events

	Days 3 and 4 only,a n (%)			Entire 28-day study period, n (%)
	p.o.	i.v.	Pooled	Pooled
Any	8 (36)	10 (45)	14 (64)	21 (95)
Headache	3 (14)	4 (18)	6 (27)	9 (41)
Nausea	1 (5)	2 (9)	3 (14)	9 (41)
Constipation	0	1 (5)	1 (5)	6 (27)
Anemia	0	0	0	5 (23)
Vomiting	1 (5)	2 (9)	3 (14)	5 (23)
Dizziness	2 (9)	1 (5)	3 (14)	4 (18)
Leukopenia	0	0	0	4 (18)
Neutropenia	0	0	0	3 (14)
Thrombocytopenia	0	0	0	3 (14)

p.o. oral, i.v. intravenous

^aReports treatment-emergent adverse events not previously reported on days 1 and 2